Northwire Canada EditionFriday, October 16, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4186.90 +0.4% SILVER 57.40 +0.4% COPPER 6.59 +0.5% OIL 96.85 −1.1% PALLADIUM 1120.25 −0.7% MON 0.385 −6.1% OMI 0.255 +2.0% BUFF 0.800 +2.6% FEO 0.670 +3.1% LIB 0.700 −2.8% NPR 0.640 +3.2% QZM 0.380 +0.0% BVA 0.750 −1.3% ONAU 0.530 +1.9% FMR 0.225 +0.0% GSVR 0.350 +2.9% PHNM 0.345 +1.5% SLG 5.63 −1.4% CASA 0.065 +8.3% DRY 0.220 +2.3% SOMA 0.580 +3.6% GOLD 4186.90 +0.4% SILVER 57.40 +0.4% COPPER 6.59 +0.5% OIL 96.85 −1.1% PALLADIUM 1120.25 −0.7% MON 0.385 −6.1% OMI 0.255 +2.0% BUFF 0.800 +2.6% FEO 0.670 +3.1% LIB 0.700 −2.8% NPR 0.640 +3.2% QZM 0.380 +0.0% BVA 0.750 −1.3% ONAU 0.530 +1.9% FMR 0.225 +0.0% GSVR 0.350 +2.9% PHNM 0.345 +1.5% SLG 5.63 −1.4% CASA 0.065 +8.3% DRY 0.220 +2.3% SOMA 0.580 +3.6%
M&A / Property

Aurora Announces Distribution Partnership with Leafio Australia

By The Northwire Desk — AI Analysis Dec 02, 2025 · 07:00 ACB · 6.37 AURORA CANNABIS INC. J
ACB · Price

Executive Summary

  • Aurora Cannabis’ Australian subsidiary, MedReleaf Australia, entered a distribution partnership with Leafio (the wholesale arm of Montu Australia) to expand patient access to its medical cannabis products across Australia.
  • The agreement gives Leafio access to Aurora’s portfolio—including MedReleaf, CraftPlant, Aurora, Whistler Cannabis Co., and IndiMed brands—and leverages Leafio’s network of over 4,000 pharmacies nationwide.
  • The partnership is positioned as a strategic move to enhance market penetration, support clinician education, and drive growth in the Australian medical cannabis market.

Key Details

  • Parties: Aurora Cannabis Inc. (via wholly‑owned subsidiary MedReleaf Australia) and Leafio (Montu Australia’s wholesale distribution arm).
  • Scope of Distribution: Leafio will act as wholesaler for Aurora’s premium medical cannabis products across its nationwide supply chain serving >4,000 pharmacies.
  • Brands Included: MedReleaf, CraftPlant, Aurora, Whistler Cannabis Co., IndiMed.
  • Strategic Rationale: Improves patient access to consistent, high‑quality medical cannabis; provides educational resources for healthcare professionals; supports research and product innovation in the region.
  • Quotes:
  • Stanley Sack, Interim Managing Director, MedReleaf Australia – highlighted combined TGA‑GMP certification and Leafio’s sector knowledge as ideal for market growth.
  • Nicole Le Maistre, General Manager, Leafio – emphasized expanded patient reach, trusted medical channels, and benefits to the industry.
  • Geographic Focus: Australia (nationwide distribution through pharmacy network).
  • Forward‑Looking Statements: Include expectations of continued growth in the Australian market, enhanced research, product innovation, and improved patient outcomes.

Notable Quotes

  • “We are excited to join forces with Leafio to improve access to consistent, high‑quality medical cannabis for Australian patients.” – Stanley Sack, Interim Managing Director, MedReleaf Australia
  • “Together, Leafio and Aurora can reach more Australian patients through trusted medical channels, bolstering access to world‑class products and expertise.” – Nicole Le Maistre, General Manager, Leafio
Read the original news release →

More from AURORA CANNABIS INC. J

Jun 11, 2026 · 07:05

Record FY2026 revenue masks structural margin contraction and explicit FY2027 guide-cut; cash-rich but capital allocation remains dilutive.

Earnings May 14, 2026 · 08:45

Aurora Cannabis Secures IP Rights Amidst Sector Consolidation and Price Stabilization

M&A / Property May 14, 2026 · 06:54

Aurora Secures IP Moat Amidst Dilution Concerns and Cash Burn

M&A / Property Apr 28, 2026 · 15:57

Aurora Cannabis Expands Global Medical Portfolio Amidst Dilution Concerns and Profitability Push

Production / Operations Apr 28, 2026 · 06:53

Product Expansion Validates EU Capacity Play, But Dilution Risk Looms Over Cash Burn

Production / Operations Apr 15, 2026 · 07:05

Aurora Cannabis Acquires EU GMP Capacity Amidst Stock Decline

M&A / Property